Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal mixed signals. While there are positive aspects such as improved cash flow, product launches, and strategic focus on innovation, the overall financial outlook remains flat with significant headwinds like tariffs, lower margins, and supply chain challenges. The cautious guidance and lack of specific details on certain risks suggest a balanced market reaction, leading to a neutral sentiment prediction.
Key Financial Performance
Global Sales from Continuing Operations $2.7 billion, representing an increase of 3% year-over-year on a reported basis and a decline of 1% on an organic basis. The decline was attributed to difficult prior year comparisons, including a one-time distributor build following Hurricane Helene and the timing of certain functional costs being reclassified.
Adjusted Earnings from Continuing Operations $0.36 per diluted share, a decrease of 35% year-over-year. This was due to higher manufacturing costs, tariffs, and an unfavorable comparison to the prior year, which benefited from a timing shift in expense recognition.
Advanced Surgery Sales $304 million, growing 10% year-over-year. Growth was driven by strong demand and increased volumes for hemostats and sealants, strong commercial execution, and steady procedure volumes.
Medical Products & Therapies (MPT) Sales $1.3 billion, declining 2% year-over-year. The decline was due to lower infusion pump sales caused by a shipment and installation hold of Novum LVP and an unfavorable comparison to the prior year due to a one-time distributor build within IV Solutions.
Healthcare Systems & Technologies (HST) Sales $705 million, decreasing 2% year-over-year. The decline was attributed to a decrease in the Front Line Care division, impacted by the timing of government orders and large customer deals, as well as planned global exits in the portfolio.
Pharmaceuticals Sales $621 million, increasing 1% year-over-year. Growth was driven by a 20% increase in drug compounding, offset by a 13% decline in Injectables and Anesthesia due to supply constraints, softer demand for inhaled anesthesia products, and an unfavorable product mix.
Adjusted Operating Margin 11%, a decrease of 390 basis points year-over-year. The decline was driven by higher manufacturing costs, tariffs, and an unfavorable comparison to the prior year due to cost timing shifts.
Free Cash Flow $76 million, compared to negative $221 million in the prior year. The improvement was attributed to better cash flow generation and progress in working capital efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Dynamo Smart Hospital Stretcher: Designed to improve patient safety and care team efficiency. Received positive customer response and strong order growth.
IV Verify Line Labeling System: An automated solution launched to support safer medication administration.
XR Spine Surgical Table: Designed to support surgical teams across a range of spine procedures.
AI-integrated solutions: Active pipeline of differentiated solutions with integrated AI functionality to accelerate future growth. Leveraging AI in Connected Care Foundation and Front Line Care to enhance clinical insights and operational efficiency.
Advanced Surgery: Achieved 10% growth in Q1 2026, driven by strong demand and increased volumes for hemostats and sealants.
Care and Connectivity Solutions: Sustained a strong order book, particularly in the U.S. Patient Support Systems portfolio.
Baxter Growth and Performance System (GPS): Implemented to simplify processes, leverage data, and strengthen performance management. Over 230 continuous improvement events launched, focusing on cash flow, service reliability, and speed to market.
AI tools for internal processes: Deployed AI tools to enhance efficiency in quality workflows, customer correspondence, and corrective field action communications.
Free Cash Flow Improvement: Generated $76 million in Q1 2026, reflecting progress in working capital efficiency and cash flow generation.
Balance Sheet Strengthening: Focused on improving free cash flow to support deleveraging, targeting net leverage of approximately 3x by the end of 2026.
Capital Deployment: Prioritizing debt paydown with plans for strategic tuck-in M&A and potential share repurchases after achieving leverage goals.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs and Higher Manufacturing Costs: The company faced headwinds from tariffs and higher manufacturing costs, including absorption, which pressured operating margins. This is expected to have a full-year impact of approximately $80 million, representing a year-over-year headwind of $40 million.
Infusion Pump Platform Issues: Lower infusion pump sales were reported due to a shipment and installation hold of the Novum LVP. The company is working on hardware and software corrections to resolve active field actions, but the timing remains uncertain.
Supply Constraints in Pharmaceuticals: The Pharmaceuticals segment faced supply constraints, including disruptions at a contract manufacturer, which negatively impacted the Injectables portfolio. These constraints are expected to persist into 2027.
Macroeconomic Uncertainty: Broader macroeconomic uncertainties, including higher oil prices and geopolitical conflicts in the Middle East, were noted as potential risks. Although the company's direct exposure to the Middle East is less than 2% of total revenue, the situation is being actively monitored.
Regulatory and Operational Challenges: The company is addressing regulatory and operational matters related to its infusion pump platform and other areas, which could impact performance if not resolved effectively.
Unfavorable Year-over-Year Comparisons: The first quarter faced unfavorable comparisons to the prior year due to one-time benefits in 2025, including a distributor build following Hurricane Helene and cost timing shifts. This created a challenging baseline for performance.
Soft Demand for Anesthesia Products: The Anesthesia portfolio experienced continued softer demand globally, contributing to a decline in the Pharmaceuticals segment.
Potential Customer Returns: Although no material impact from Novum LVP-related returns was observed in the first quarter, the company has factored this possibility into its full-year guidance.
Timing of Installations in Care Communications: The Care Communications portfolio within the Healthcare Systems & Technologies segment was impacted by the timing of installations, which affected performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2026 Financial Outlook: Baxter expects total sales growth to be flat to 1% on a reported basis, with foreign exchange contributing approximately 100 basis points to growth. Organic sales growth is expected to be flat. Adjusted operating margin is projected to range between 13% to 14%, and adjusted earnings per share are anticipated to be between $1.85 and $2.05. Free cash flow is expected to be back half-weighted.
Segment-Level Guidance: Medical Products & Therapies (MPT) segment is expected to have flat to slightly up organic sales for the full year, with the Novum shipment and installation hold factored into guidance. Healthcare Systems & Technologies (HST) segment is projected to grow low single digits organically, supported by new product launches and a strong order book. Pharmaceuticals segment is expected to have flat organic sales, with ongoing pressures in Injectables & Anesthesia offset by growth in drug compounding.
Second Half 2026 Performance: Improvement in organic sales growth, operating margin, and adjusted earnings is expected in the second half of 2026. Key drivers include higher volumes, benefits from cost structure actions, and rolling through higher cost inventory. Operating margin improvement is anticipated to be approximately 500 basis points from the first half to the second half.
Capital Deployment and Leverage: Baxter aims to improve free cash flow to support deleveraging, targeting net leverage of approximately 3x by the end of 2026. Near-term capital deployment priority is debt paydown, with future optionality for strategic tuck-in M&A and share repurchases once leverage goals are achieved.
Product Innovation and AI Integration: Baxter plans to advance innovation with new product launches, including Connex 360 and Dynamo, and integrate AI into internal processes, frontline workflows, and manufacturing to enhance efficiency and reliability. AI-assisted corrective field action communications are scheduled for deployment later in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: Our near-term capital deployment priority is debt paydown, and we continue to target net leverage of approximately 3x by the end of 2026. Once we reach our leverage goal, we will have a stronger balance sheet with more optionality to drive shareholder value, including strategic tuck-in M&A that enhances our customer offerings and growth profile as well as the option to return capital through share repurchases.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How does the first quarter performance translate into the reiterated guidance, and what are the expectations for Q2?
A:The first quarter came in overall in line with expectations. There was no material impact from Novum customers, but potential risks are still considered in the guidance. Sequential improvement is expected from Q1 to Q2 on the top line, but year-over-year pressures will persist. Full-year guidance remains approximately flat, with known pressures in the first half and improvement in the second half.
Q:What are the expectations for 2027, including new product launches and EPS growth?
A:While no specific guidance is provided, modest growth in 2027 is expected, including earnings growth. Key product launches include Connex 360 and Dynamo stretcher, which have received positive customer feedback. Innovation will be a key driver for future growth.
Q:What is the outlook for the MPT business, particularly regarding Novum and IV set businesses?
A:The Novum syringe has been launched, and the Spectrum LVP platform continues to receive strong customer feedback. Pump revenue is expected to grow in the back half of the year. The company is staying close to its customer base to support growth.
Q:What gives confidence in the significant ramp in the back half of the year?
A:Confidence comes from seasonality, strong customer interest, normalization of IV Solutions business by 2026, and expected low single-digit growth in HST. The company is focused on executing its KPIs and ensuring clarity and focus.
Q:What is the impact of inflation on operating margins, and how is the company managing cost pressures?
A:The impact of oil prices has been mitigated due to the sale of the Kidney Care business, reducing exposure to less than 50%. The company is proactively managing supply chain risks, including dual sourcing and supplier engagement. Inflation is being monitored closely, but the company is not immune to macro trends.
Q:What is the progress on the turnaround plan and any strategic changes?
A:The CEO has been focused on restoring Baxter as an industry leader, with efforts gaining traction. The company has conducted over 230 events in Q1 to build momentum and is focused on executing its turnaround plan with a long-term perspective.
Q:Why is the guidance for organic growth flat despite Q1 performance?
A:Q1 performance was in line with expectations, but potential risks from Novum customers and year-over-year headwinds in injectables and Novum are factored into the guidance. HST growth is expected in the back half of the year.
Q:What are the HST order trends and growth expectations?
A:HST performance in Q1 was driven by Front Line Care, with some timing aspects and planned exits. CCS was roughly flat, with growth in PSS. HST is expected to grow low single digits for the year, weighted to the back half.
Q:How is the company addressing supply chain challenges, including chips?
A:The company has not experienced material shortages in memory chips but is proactively managing risks through disciplined forecasting, supplier engagement, and dual sourcing. Supply chain challenges are being closely monitored.
Q:What is the company's approach to innovation and growth?
A:The company is focused on disciplined capital allocation and investing in innovation as a key enabler for future growth. Innovation efforts are decentralized and customer-focused, with early successes like Connex 360 and Dynamo. The company aims to drive growth and ROIC through continuous innovation.
Q:What is the status of the Novum returns and potential refiling?
A:Novum returns have been immaterial to results so far, but potential risks are included in the guidance. The company is finalizing hardware and software corrections and will implement them in accordance with regulatory authorities, including any necessary submissions.
Q:What is the outlook for Injectables & Anesthesia and the CFO search?
A:Injectables & Anesthesia are expected to improve in the back half of the year. Challenges with operations and a contract manufacturer are being addressed. The CFO search is well underway, with strong interest from candidates.
Q:What is the company's mitigation plan for inflation in 2027?
A:While no specific guidance is provided for 2027, the company is focused on mitigating supply chain risks and inflationary pressures through proactive measures and monitoring.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the potential risk of Novum returns, the exact impact of inflation in 2027, and the precise growth expectations for 2027. Responses were often general, emphasizing ongoing efforts and confidence without concrete data or timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Accounting Officer
Care
Chief Accounting
GPS
Interim
International
Middle East
Mr
Novum
System
accountability
business
challenge
consistency
culture improvement
direction
divestiture
enterprise
event
example order
exposure
field action
headwind
insight
investor presentation
leader
manufacturing
outlook press
potential
power
press release
release investor
reliability
safety
shareholder value
speed
successor
turnaround
workflow
BAX Transcript
Baxter International Inc. (BAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call summary and Q&A reveal mixed signals. While there are positive aspects such as improved cash flow, product launches, and strategic focus on innovation, the overall financial outlook remains flat with significant headwinds like tariffs, lower margins, and supply chain challenges. The cautious guidance and lack of specific details on certain risks suggest a balanced market reaction, leading to a neutral sentiment prediction.
Baxter International Inc. (BAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
BAX Slides
BAX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
